Lord, Abbett & Co’s ALX Oncology ALXO Stock Holding History

Lord, Abbett & Co’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-556,622	Closed	-$41.1M	–	602
2021 Q3	$41.1M	Buy	+556,622	New	+$37.1M	0.1%	303

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Lord, Abbett & Co's ALXO Position: Q4 2021 in Review

Lord, Abbett & Co sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 556,622 shares — an estimated $41.1M sold.

Lord, Abbett & Co first reported a position in ALXO in Q3 2021 and held it in 1 quarter. The position peaked at $41.1M in Q3 2021. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

Lord, Abbett & Co reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
Lord, Abbett & Co sold 556,622 ALX Oncology shares in Q4 2021, an estimated $41.1M.
Lord, Abbett & Co first reported a position in ALX Oncology in Q3 2021 and held it in 1 quarter.
Lord, Abbett & Co's ALX Oncology position peaked at $41.1M in Q3 2021.
108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on Lord, Abbett & Co's 13F filing for Q4 2021, filed 11 Feb 2022.